1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

27 Jun 2024
Admin
News Article

Helsinn Group Launches Akynzeo Injection in US Market

Overview

Helsinn Group, a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, announced that Akynzeo (fosnetupitant/palonosetron) injection is now available in the US in a ready-to-use vial.

About Akynzeo Injection

Akynzeo injection (ready-to-use) is a new method of administration and contains the same formulation as the prior Akynzeo injection (to-be-diluted).

Features

The features of the new ready-to-use presentation of Akynzeo injection include:

No reconstitution or dilution required;
Infuse directly from the vial using a built-in hanging strap;
No refrigeration required at any point during distribution, storage, or preparation;
Accessible via automated dispensing machine, allowing the product to be stored and available near the location of patient care.

Indication

Akynzeo injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.
It has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy.
Akynzeo injection does not contain polysorbate 80 or allergenic excipients such as soy or egg lecithin.
It can be administered simultaneously with intravenous dexamethasone sodium phosphate.

Words from CEO: Helsinn Group

Dr. Melanie Rolli, Helsinn Group CEO, commented: “As a pioneer in cancer supportive care, Helsinn continues to be unwavering in our pursuit to help patients and clinicians in cancer care. We are very pleased to launch the new Akynzeo ready-to-use vial, building on our legacy of innovation.”

To order New Vials

Clinicians wishing to order the new vial should contact their GPO or distributor.
The National Drug Code (NDC) number for Akynzeo injection vial with hanger (Ready-to-Use) is 69639-106-01 and the J Code is J1454 (injection, fosnetupitant 235 mg and palonosetron 0.25 mg); billing unit (single dose vial [SDV]).

About Akynzeo

Akynzeo is the first and only 5-HT3 and NK1 receptor antagonists fixed combination approved for the prevention of chemotherapy-induced acute and delayed nausea and vomiting.
A single dose of Akynzeo given with dexamethasone has been shown to prevent chemotherapy-induced nausea and vomiting for up to 5 days.

Akynzeo Indication

Akynzeo (fosnetupitant/palonosetron) injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.

Limitations of Use:

Akynzeo injection has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy.

Constituents of Akynzeo

Akynzeo is a combination of palonosetron, a serotonin-3 (5-HT3) receptor antagonist, and fosnetupitant, a substance P/neurokinin-1 (NK-1) receptor antagonist: palonosetron prevents nausea and vomiting during the acute phase and fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!